Explain me prostate cancer. I need to study this for my urology class. Our proffoser asks questions like we are doctors in urology speciality for 10yrs. I hope you understand how deep he asks questions. So explain everything about prostate cancer to me. Some of the things that you can't miss are Classification, Etiology, pathogenesis, symptoms and signs (where, how,severity etc etc), diagnosis, clinical manifestations, prognosis, treatment. These are some must give details you have to give me more information than this. Understood?

Reading File

Finding Sources

The key sources are Campbell Walsh Wein Urology (the gold standard urology textbook), Robbins Pathology, and Harrison's. Let me now read the most important blocks in parallel.

Reading File

Excellent content from Harrison's and Robbins. Let me read more from the prostate cancer sections, particularly from Harrison's (block10.md continues) and Robbins, plus Campbell Walsh for staging/treatment.

Reading File

Finding Sources

Excellent detail from Harrison's and Robbins. Now let me continue reading Harrison's prostate cancer section and get more content on staging, treatment, and prognosis, plus get images.

Reading File

Searching Images

prostate cancer Gleason grading histology adenocarcinoma

Excellent. Now let me read more of Harrison's treatment section and Robbins' grading/staging section to get the full clinical picture, plus search for more images.

Reading File

Searching Images

prostate cancer TNM staging bone metastases osteoblastic

Excellent data. Let me continue reading the Harrison's treatment section and get the full Robbins staging/treatment content.

Reading File

I have the full TNM staging table and Gleason groups from Robbins. Let me now read the Harrison's treatment section further and get the treatment of metastatic disease content.

Reading File

Searching PubMed

prostate cancer treatment guidelines 2024

I now have a comprehensive picture from Harrison's, Robbins, and current EAU guidelines. Let me mark the research tasks done and now synthesize the complete answer.Here is a comprehensive, specialist-level deep dive on prostate cancer. This is compiled from Campbell Walsh Wein Urology, Harrison's Principles of Internal Medicine 22e, Robbins & Cotran Pathologic Basis of Disease, and the 2024 EAU Guidelines (PMID 38614820, 38688773).

Prostate Cancer — A Complete Reference

1. EPIDEMIOLOGY

Prostate cancer is the most common non-skin malignancy in men and the second leading cause of cancer death in males in the United States. The American Cancer Society estimated 299,010 new cases and 35,250 deaths in the US in 2024 alone. The incidence/mortality ratio is extremely high — most men diagnosed will not die from their disease.

Prevalence by autopsy: ~70% of men in their 8th decade show histologic evidence of prostate cancer
Age: Peak incidence after 65; rare before 40
Race: African-American men have significantly higher incidence, present at more advanced stage, with higher-grade, more aggressive disease — attributed to genetic, environmental, and societal factors
Geography: Autopsy-detected prevalence is similar worldwide; clinical incidence varies enormously due to PSA screening availability — Asian men who migrate to Western environments show increased risk

— Harrison's Principles of Internal Medicine 22e, p. 739

2. ETIOLOGY & RISK FACTORS

Non-modifiable

Factor	Detail
Age	Most important single risk factor; incidence rises steeply after 50
Family history	2.5× higher risk if one first-degree relative affected; risk amplifies with more relatives and if diagnosed <65
Hereditary	40% of early-onset and 5–10% of all prostate cancers are hereditary
Germline mutations	BRCA2 (most significant), BRCA1, HOXB13, ATM, PALB2 — these substantially increase risk
Ethnicity	Black > White > Asian
GWAS risk loci	>100 susceptibility loci identified; explain up to 25% of prostate cancer risk

Modifiable / Environmental

High dietary fat (α-linolenic acid, polycyclic aromatic hydrocarbons from charred red meat) — increases risk
Obesity — associated with more aggressive disease
Smoking — increases risk of disease progression
Protective: lycopene (tomatoes), statins (cholesterol inhibition), possible protective effect of selenium and vitamin E (though large trials negative)

— Harrison's 22e, p. 740; Robbins, p. 909

3. ANATOMY & ZONES OF ORIGIN

The prostate has four zones:

Peripheral zone (70% of glandular tissue): ~70% of prostate cancers arise here — posterior location, often palpable on DRE
Transition zone: Site of BPH; ~25% of prostate cancers arise here (usually incidentally found at TURP)
Central zone: ~5% of cancers
Periurethral (anterior fibromuscular stroma): Rarely site of cancer

Critical distinction for exams: BPH originates in the transition zone; carcinoma predominantly in the peripheral zone.

The prostate's anatomical neighbors are critical for understanding spread: the rectum (posterior), bladder neck (superior), external sphincter (inferior), neurovascular bundles (posterolateral — responsible for erection), and ureters.

4. PATHOGENESIS & MOLECULAR BIOLOGY

Androgen Dependence

Both normal prostate epithelium and prostate cancer cells are androgen dependent. Testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase type 2 within prostate cells. DHT binds androgen receptors (ARs) with higher affinity than testosterone, translocates to the nucleus, and activates androgen-dependent gene transcription driving proliferation and survival.

Key Molecular Events

ETS gene fusions (most common driver): The TMPRSS2:ERG fusion occurs in ~50% of prostate cancers. TMPRSS2 is androgen-regulated; this places ERG (an oncogenic transcription factor) under androgen control — creating a self-amplifying oncogenic loop. Fusions with ETV1, ETV4 also occur.
PTEN loss: PTEN is a tumor suppressor that negatively regulates the PI3K/AKT/mTOR pathway. Loss of PTEN (found in ~40% of cancers) drives proliferation and survival. Inversely correlated with ERG fusion.
p53 mutations: More common in advanced/castration-resistant disease
RB1 deletion: Promotes cell cycle entry
AR amplification/mutation: Central to castration-resistant prostate cancer (CRPC) — AR is re-activated despite castrate testosterone levels
CDK12 mutations: Associated with genomic instability and AR-independent signaling
BRCA2/ATM/CDK12: DNA repair pathway mutations — important for PARP inhibitor sensitivity

Precursor Lesion

High-grade Prostatic Intraepithelial Neoplasia (HGPIN): architecturally benign large acini lined by cytologically atypical cells (enlarged nuclei, prominent nucleoli). HGPIN retains a basal cell layer (unlike cancer). Found in ~80% of prostatic specimens harboring carcinoma. Considered the main precursor.

— Robbins, p. 908; Harrison's 22e

5. PATHOLOGY & CLASSIFICATION

Histological Type

Acinar adenocarcinoma: >95% of cases — this is "prostate cancer" by default
Ductal adenocarcinoma
Mucinous adenocarcinoma
Signet ring cell carcinoma
Squamous cell carcinoma
Transitional cell carcinoma (urothelial)
Neuroendocrine (small cell): Rare but highly aggressive; androgen-independent; associated with treatment-induced neuroendocrine differentiation

Gross Pathology

Arises in peripheral zone → gritty, firm, gray-white on cross-section (contrast to spongy BPH nodules)
May be difficult to visualize by eye in early disease

Microscopic Features of Adenocarcinoma

Feature	Malignant Glands	Benign Glands
Gland architecture	Small, crowded, back-to-back	Larger, branching, papillary
Basal cell layer	Absent (hallmark)	Present
Nuclei	Enlarged, prominent nucleoli	Small, inconspicuous
Cytoplasm	Amphophilic (pale-clear to dark)	Pale
Branching	Absent	Present

Key diagnostic markers:

AMACR (α-methylacyl-CoA racemase / P504S): Positive in 82–100% of prostate cancers — marks the malignant glands
p63 / CK5/6 / CK903: Basal cell markers — positive in benign glands, negative in cancer
PSA: Positive in both benign and malignant prostatic epithelium (not cancer-specific)
Perineural invasion: Highly specific for malignancy when present

Low-grade prostatic acinar adenocarcinoma (Gleason 3+3=6)

Low-grade prostatic adenocarcinoma with well-formed, back-to-back glands, absent basal cell layer. (Gleason 3+3=6)

High-grade cribriform pattern (Gleason 4+4=8) — irregular glands, cytologic atypia, minimal intervening benign tissue.

6. GRADING — GLEASON SYSTEM & GRADE GROUPS

The Gleason system grades the two most prevalent architectural patterns (primary + secondary) from 1–5, and sums them for a score from 2–10. In modern practice, Gleason score 2–5 is no longer assigned; minimum assigned is 6.

Five Grade Groups (ISUP 2014 / WHO 2016)

Grade Group	Gleason Score	Description
1	≤6 (3+3)	Only individual, discrete, well-formed glands
2	3+4=7	Predominantly well-formed glands + lesser component poorly formed/fused/cribriform
3	4+3=7	Predominantly poorly formed/fused/cribriform + lesser well-formed
4	4+4=8; 3+5=8; 5+3=8	Only poorly formed/fused/cribriform glands OR mix of well-formed and lack of glands
5	4+5=9; 5+4=9; 5+5=10	Lack of gland formation (or necrosis) ± poorly formed/cribriform glands

Clinical correlation: Grade Group 1 = favorable, often managed by active surveillance. Grade Groups 4–5 = high-risk, typically require aggressive treatment.

The Gleason Grading System — architectural patterns 1–5 and how they combine to produce a score.

Important nuance: When only one pattern is present, it is doubled (e.g., 3+3=6). The highest-grade pattern (even if tertiary/minor) must be reported if it is grade 4 or 5, because it significantly impacts prognosis.

— Robbins, p. 909; Harrison's 22e, p. 741

7. STAGING — TNM SYSTEM (AJCC 8th Edition)

Clinical T Stage

Stage	Definition
T1	Clinically inapparent — not palpable, not visible on imaging
T1a	Incidental histologic finding in ≤5% of resected tissue (TURP)
T1b	Incidental in >5% resected tissue
T1c	Found by needle biopsy (elevated PSA only)
T2	Tumor confined within prostate
T2a	≤ half of one lobe
T2b	> half of one lobe, not both
T2c	Both lobes
T3	Extracapsular extension
T3a	Extracapsular extension (unilateral or bilateral)
T3b	Seminal vesicle invasion
T4	Fixed, or invades adjacent structures (external sphincter, rectum, bladder, levator muscles, pelvic wall)

Pathological T Stage (pTNM)

Note: pT1 does not exist (can't assess T1 on a radical prostatectomy specimen). pT2 = organ confined; pT3a = extraprostatic extension ± bladder neck; pT3b = seminal vesicle invasion; pT4 = other adjacent structures.

N Stage

| N0 | No regional nodal metastasis | | N1 | Regional lymph node metastasis (obturator → iliac → paraaortic) |

M Stage

| M0 | No distant metastasis | | M1a | Non-regional lymph nodes | | M1b | Bone metastases (most common) | | M1c | Other distant sites (visceral) |

Risk Stratification (D'Amico / AUA / EAU)

Risk Group	PSA	Grade Group	cT Stage
Very Low	<10 ng/mL	1	T1c; <3 biopsy cores; <50% any core
Low	<10 ng/mL	1	T1–T2a
Intermediate Favorable	10–20 ng/mL	2	T2b–c
Intermediate Unfavorable	10–20 ng/mL	3	or multiple intermediate factors
High	>20 ng/mL	4–5	T3a
Very High	Any	5	T3b–T4, >4 cores GG4+, primary Gleason 5
Metastatic (M1)	Any	Any	N1 or M1

8. CLINICAL MANIFESTATIONS & SYMPTOMS

Localized Disease (T1–T2)

Often completely asymptomatic — most cases today are detected via PSA screening.

Locally Advanced Disease (T3–T4)

Lower urinary tract symptoms (LUTS): Hesitancy, weak stream, nocturia, frequency, urgency — due to urethral compression (overlap with BPH; symptom profile alone cannot distinguish)
Hematuria / hemospermia: With invasion into urethra or seminal vesicles
Ureteral obstruction: Hydronephrosis, renal failure when tumor extends to bladder base
Erectile dysfunction: From neurovascular bundle involvement
Rectal symptoms: From posterior invasion — rare

DRE Findings

Hard, nodular, irregular nodule — typically in the posterior peripheral zone
Asymmetric or fixed gland in advanced disease
20–25% of patients with an abnormal DRE have prostate cancer; DRE sensitivity for early disease is poor

Metastatic Disease

The pattern of metastasis follows anatomical lymphatics and vascular routes:

Lymphatic spread (in order): Obturator nodes → Internal/external iliac → Common iliac → Para-aortic nodes

Hematogenous spread: Preferentially to axial skeleton via the Batson's vertebral venous plexus (valve-less, bidirectional):

Lumbar spine (most common)
Proximal femur
Pelvis
Thoracic spine
Ribs

Bone metastases are characteristically OSTEOBLASTIC (sclerotic) — this is pathognomonic of prostate cancer origin in adult males. The mechanism is tumor-derived growth factors stimulating osteoblast activity while simultaneously stimulating osteoclasts (net osteoblastic effect).

Symptoms of metastatic disease:

Bone pain: Deep, constant, progressive back/hip pain — initially nocturnal, later continuous
Pathological fractures
Spinal cord compression: Epidural extension → acute lower limb weakness, saddle anesthesia, bowel/bladder dysfunction — oncologic emergency
Hypercalcemia: Less common than osteolytic tumors but can occur
Anemia: Marrow infiltration → leukoerythroblastic picture
Lymphedema: Lower limb edema from lymph node obstruction
Ureteral obstruction / hydronephrosis

Osteoblastic bone metastases from prostate cancer — whole-body bone scan

Whole-body bone scintigraphy (Tc-99m MDP) showing osteoblastic metastases from prostate adenocarcinoma in the cervical spine and sacrum.

Vertebral osteoblastic metastasis — gross pathology

Gross pathology of vertebral body metastasis from prostate cancer — ivory-white sclerotic osteoblastic pattern.

— Robbins, p. 908–910; Harrison's 22e

9. DIAGNOSIS

PSA (Prostate-Specific Antigen)

A kallikrein-related serine protease (KLK3) — produced by both benign and malignant prostatic epithelium
Organ-specific, not cancer-specific: Also elevated in BPH, prostatitis, prostate infarction, ejaculation, urethral instrumentation
In blood: exists as free PSA and complexed (mainly with α₁-antichymotrypsin)
Lower free:total PSA ratio → higher probability of cancer
Standard cut-off: ≥4 ng/mL for biopsy; however there is no zero-risk PSA level
After radical prostatectomy: should be undetectable by 6 weeks; any detectable PSA = biochemical recurrence/residual disease

PSA derivative tests to improve specificity:

Test	Description
PSA density	PSA / prostate volume (TRUS); >0.15 suspicious
PSA velocity	Rate of PSA rise >0.75 ng/mL/year
Free PSA ratio	Free/total PSA <10% → higher cancer risk
PSA doubling time	Rapid doubling (<3 months) = aggressive biology
4K Score	Combines total PSA, free PSA, intact PSA, hK2 + clinical factors → % risk of high-grade cancer
PHI (Prostate Health Index)	Combines [-2]proPSA, free PSA, total PSA → better predictor than PSA alone
SelectMDx / ExoDx	Urine-based mRNA/exosome markers

Digital Rectal Examination (DRE)

Mandatory component of evaluation
Detects posterior peripheral zone tumors
Sensitivity/specificity insufficient for standalone screening
~20–25% of abnormal DREs have cancer on biopsy

Multiparametric MRI (mpMRI) — Now Standard of Care

Before biopsy in most guidelines. Combines:

T2-weighted (anatomy, peripheral zone, capsular integrity)
Diffusion-weighted imaging (DWI) — restricted diffusion in high-cellularity tumors (low ADC)
Dynamic contrast-enhanced (DCE) — abnormal vascularity
MR spectroscopy (optional) — elevated choline:citrate ratio

Findings scored using PI-RADS v2.1 (1–5):

PI-RADS 1–2: Low probability of clinically significant cancer
PI-RADS 3: Intermediate; biopsy based on clinical context
PI-RADS 4–5: High probability; biopsy recommended

Prostate Biopsy

TRUS-guided systematic biopsy: Standard; 10–12 core systematic sampling
MRI-targeted biopsy (fusion biopsy): MRI-visible lesion + systematic cores — significantly improves detection of clinically significant cancers (GG ≥2) and reduces overdetection of GG1
Transperineal approach: Lower risk of sepsis vs. transrectal; increasingly preferred post-antibiotic resistance concerns

Imaging for Staging

Modality	Use
Bone scan (Tc-99m MDP)	Standard for bone metastasis detection; indicated when PSA >10–20 or high-risk features
CT abdomen/pelvis	Lymph node staging (limited sensitivity for <8mm nodes)
PSMA PET/CT	Highly sensitive/specific for nodal and distant metastasis; FDA-approved (⁶⁸Ga-PSMA-11, ¹⁸F-DCFPyL); superior to bone scan + CT; increasingly replacing conventional imaging
Whole-body MRI	Alternative for metastasis detection, especially bone marrow
¹¹C-choline PET	Earlier agent; useful for biochemical recurrence detection

MRI whole-body staging of prostate cancer — combined T-N-M in one protocol

Multiparametric MRI protocol combining local T-staging (axial), DWI whole-body for N/M staging, and sagittal PDFS for vertebral marrow assessment.

Laboratory Investigations

Serum PSA (baseline; serial measurements for monitoring)
Alkaline phosphatase (ALP): Elevated in osteoblastic bone metastases (bone ALP isoform)
LDH: Tumor burden marker in metastatic disease
Testosterone: Baseline pre-ADT; castrate level = <50 ng/dL (<1.7 nmol/L)
CBC: For anemia (marrow infiltration); pre-treatment baseline
BMP/creatinine: For obstruction assessment
Germline testing: Recommended for high-risk, metastatic, or family history (BRCA1/2, ATM, PALB2, MLH1, MSH2, MSH6, PMS2, HOXB13)
Somatic tumor testing: For BRCA2/ATM (PARP inhibitor eligibility), MSI-H/dMMR (pembrolizumab eligibility), CDK12 mutation

10. CLINICAL STATES MODEL (Harrison's Framework)

Prostate cancer management is organized around clinical states:

No cancer diagnosis (screening/prevention)
Clinically localized disease (organ-confined)
Biochemical recurrence after local therapy (rising PSA, no imaging evidence of metastasis)
Metastatic disease — further subdivided:
- mHSPC: Metastatic hormone-sensitive (castration-naive)
- nmCRPC: Non-metastatic castration-resistant (rising PSA on ADT, no imaging metastasis)
- mCRPC: Metastatic castration-resistant

This model is critical because treatment decisions and goals differ at each state.

11. TREATMENT

11a. Localized Disease

Very Low / Low Risk

Active Surveillance (AS): First-line for GG1 (Gleason 6) and selected GG2 patients. Serial PSA, DRE, mpMRI, and repeat biopsies. Deferred treatment until evidence of progression. Avoids overtreatment. >90% of GG1 patients will not need immediate intervention.
Watchful Waiting: Different from AS — no curative intent; palliative intervention only if symptomatic. Used for older men with limited life expectancy.

Localized Intermediate/High Risk — Definitive (Curative) Treatment

Radical Prostatectomy (RP):

Open, laparoscopic, or robotic-assisted (RALP) — robotic now predominates
Standard: nerve-sparing RP (if oncologically safe) to preserve potency + continence
Extended pelvic lymph node dissection (ePLND): Required for intermediate/high-risk
Specimen assessment: pT stage, Gleason grade, surgical margins (positive margin = higher recurrence risk), lymph node status
Oncologic outcomes: >90% 15-year survival for high-risk disease treated definitively
Complications: Urinary incontinence (stress incontinence; 5–15% long-term), erectile dysfunction (30–80% depending on nerve-sparing and patient age)

Radiation Therapy:

External Beam Radiation Therapy (EBRT): Intensity-modulated RT (IMRT) is standard; daily fractions; total ~70–80 Gy; MRI-guided RT emerging
Stereotactic Body Radiation Therapy (SBRT): Hypofractionated; 5 sessions; equivalent oncologic outcomes; growing evidence
Low-dose rate brachytherapy (LDR-BT): Permanent seed implantation (¹²⁵I, ¹⁰³Pd); for low/selected intermediate risk; excellent long-term outcomes
High-dose rate brachytherapy (HDR-BT): Temporary implant; used as boost with EBRT for high-risk
Combined EBRT + ADT for 2–3 years: Standard of care for high-risk localized disease (Gleason 8–10, T3–T4)
Complications: Radiation proctitis, urinary frequency/urgency, erectile dysfunction (delayed onset)

Other Local Therapies:

Focal therapy (for carefully selected intermediate risk): HIFU (High-Intensity Focused Ultrasound), focal cryoablation, irreversible electroporation — ablate only MRI-visible index lesion. Still investigational for most guidelines but EAU considers it in selected patients.

11b. Biochemical Recurrence (BCR) After Primary Treatment

PSA rising post-prostatectomy (detectable/rising PSA) or post-radiation (Phoenix definition: PSA rise ≥2 ng/mL above nadir)
Salvage RT to prostate bed: First-line after RP if PSA is rising; most effective when PSA <0.5 ng/mL
Salvage RP: After failed radiation; technically demanding; increased morbidity
ADT: For those with short PSA doubling time (<3 months), high Gleason grade, or nodal recurrence on PSMA PET
PSMA PET/CT: Critical to identify site of recurrence; guides salvage treatment

11c. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

The backbone of treatment is Androgen Deprivation Therapy (ADT) — surgical or medical castration:

Surgical: Bilateral orchiectomy — permanent, immediate, cost-effective; castrate testosterone within hours

Medical (LHRH agonists): Leuprolide, goserelin, triptorelin — chronic administration causes receptor downregulation → pituitary desensitization → ↓ LH → ↓ testicular testosterone. Testosterone flare in first 1–2 weeks (requires short-term antiandrogen coverage with bicalutamide/flutamide).

LHRH antagonists: Degarelix, relugolix — direct receptor blockade, no flare, faster castration; relugolix is oral

Androgen receptor pathway inhibitors (ARPIs): Second-generation; crucial now

Agent	Class	Mechanism
Enzalutamide	ARPI	AR antagonist; inhibits nuclear translocation and DNA binding
Apalutamide	ARPI	AR antagonist
Darolutamide	ARPI	AR antagonist; minimal CNS penetration
Abiraterone + prednisone	CYP17A1 inhibitor	Blocks androgen synthesis in adrenal glands AND tumor

Current standard of care for mHSPC: ADT + intensification

ADT + docetaxel (CHAARTED, STAMPEDE trials): Benefit mostly in high-volume disease
ADT + ARPI (enzalutamide, apalutamide, or darolutamide + docetaxel): Demonstrated significant overall survival benefit; now standard
ADT + abiraterone + prednisone (LATITUDE trial): Improved OS in high-risk mHSPC
Triplet therapy (ADT + docetaxel + abiraterone, or ADT + docetaxel + darolutamide) — ARASENS, PEACE-1 trials support triplet in high-volume/high-risk

11d. Castration-Resistant Prostate Cancer (CRPC)

Defined as disease progression (PSA or radiographic) despite castrate testosterone levels (<50 ng/dL). AR re-activation is the dominant mechanism:

AR amplification/overexpression
AR ligand-binding domain mutations (e.g., F877L from enzalutamide selection; W742C from bicalutamide)
AR splice variants (AR-V7): Constitutively active; lack ligand-binding domain → resistance to ARPIs
Intratumoral androgen synthesis
Lineage plasticity — neuroendocrine differentiation

Treatment of mCRPC

Agent	Mechanism	Indication
Enzalutamide, apalutamide	ARPI	mCRPC; pre/post-docetaxel
Abiraterone + prednisone	CYP17A1 inhibitor	mCRPC
Docetaxel (75 mg/m², q3wk + prednisone)	Taxane	First chemo line
Cabazitaxel (25 mg/m², q3wk)	Taxane	Post-docetaxel
Olaparib	PARP inhibitor	mCRPC with BRCA1/2 or other HRR mutations (PROfound)
Rucaparib	PARP inhibitor	Post-docetaxel + ARPI with BRCA mutations
Pembrolizumab	Anti-PD-1	MSI-H/dMMR or TMB-high tumors
¹⁷⁷Lu-PSMA-617 (Lutetium PSMA)	Targeted radioligand therapy	mCRPC post-ARPI + taxane (TheraP, VISION trials); FDA approved 2022
Radium-223 (Ra-223)	Alpha emitter	Symptomatic bone-only mCRPC; improves OS and delays SREs
Sipuleucel-T	Autologous dendritic cell vaccine	Asymptomatic/minimally symptomatic mCRPC
Denosumab / Zoledronic acid	Anti-RANKL / Bisphosphonate	Bone-targeted agents; prevent skeletal-related events (SREs); used throughout metastatic disease

Non-metastatic CRPC (nmCRPC): Rising PSA on ADT, no imaging metastasis, PSA doubling time ≤10 months → Enzalutamide, apalutamide, or darolutamide delay metastasis-free survival significantly (SPARTAN, PROSPER, ARAMIS trials).

11e. Symptomatic Management

Bone pain: NSAIDs → opioids; bone-targeting agents (denosumab, zoledronic acid); Ra-223 for multiple symptomatic bone metastases
Spinal cord compression: Dexamethasone immediately → emergency RT or surgical decompression
Ureteral obstruction: Ureteral stents or percutaneous nephrostomy
Urinary obstruction/retention: TURP (palliative) or catheterization
ADT side effects management: Hot flashes (venlafaxine, medroxyprogesterone), osteoporosis (denosumab/bisphosphonates + calcium/D3), cardiovascular surveillance, metabolic syndrome monitoring

12. PROGNOSIS

Localized Disease

90% of patients with high-risk localized disease treated with definitive therapy survive 15 years
Gleason grade group is the single strongest histopathologic prognostic factor
pT stage + margin status + PSA level = key post-operative prognostic variables

Nomograms

Partin Tables: Pre-operative — predict pathologic stage based on PSA, Gleason score, clinical T stage
Kattan nomogram / Memorial Sloan Kettering tools: Predict biochemical recurrence-free survival after RP
D'Amico risk classification: Standard risk stratification for localized disease

Metastatic Disease

mHSPC → mCRPC conversion: Median time ~18–24 months on ADT; progression accelerated by high-volume disease, high Gleason grade
mCRPC: Median OS was historically ~14–18 months with docetaxel; modern combination approaches (ARPI + ADT, PARP inhibitors, lutetium-PSMA) have extended median OS
BRCA2-mutated mCRPC: More aggressive; however PARP inhibitors (olaparib) provide meaningful benefit
Biochemical recurrence after RP: Median time to metastasis ~8 years; time to cancer-specific death ~5 years after metastases (PSA doubling time <3 months strongly predicts lethal outcome)

Key Prognostic Factors Summary

Factor	Favorable	Unfavorable
Gleason Grade Group	1–2	4–5
PSA at diagnosis	<10	>20
Clinical stage	T1–T2	T3–T4, N1, M1
PSA doubling time	>12 months	<3 months
Metastasis volume	Low	High
AR-V7 status	Negative	Positive (ARPI resistance)
BRCA2 mutation	—	Worse prognosis (but PARP targetable)
Visceral metastases	Absent	Present (worst prognosis)

13. GENOMIC TESTING — CLINICALLY USED TODAY

Test	Type	Clinical Use
Oncotype DX GPS	17-gene expression	Active surveillance vs. definitive treatment in low-risk
Prolaris	46-gene cell-cycle panel	Risk of biochemical recurrence; treatment intensification
Decipher	22-gene expression	Predict metastasis after RP; guide adjuvant RT
ProMark	8-protein IHC	Risk stratification at biopsy
Germline BRCA1/2	Germline DNA	PARP inhibitor eligibility; family counseling
Somatic BRCA2/ATM	Tumor DNA	PARP inhibitor eligibility
MSI/dMMR	Tumor DNA	Pembrolizumab eligibility

14. SCREENING RECOMMENDATIONS (2024 Guidelines)

Organization	Recommendation
AUA 2023	Shared decision-making age 50–69; start at 40–45 for Black men, BRCA2 carriers, strong family history; every 2–4 years
USPSTF	Individual decision age 55–69; against screening ≥70
EAU 2024	Risk-adapted early detection; baseline PSA at 45–50; individualized intervals based on PSA level

PSA <1 ng/mL at age 60 → can cease screening; PSA >1 ng/mL at 60 → continue screening.

Quick-Reference Key Concepts for Your Exam

Point	Core Fact
Most common site of origin	Peripheral zone (~70%)
Most common histology	Acinar adenocarcinoma (>95%)
Key hallmark on histology	Absent basal cell layer in malignant glands
Immunohistochemical marker of cancer	AMACR/P504S positive; p63/CK5/CK903 negative
Precursor lesion	HGPIN (retains basal cells)
Key molecular alteration	TMPRSS2:ERG fusion (~50%); PTEN loss (~40%)
Bone metastasis character	Osteoblastic (sclerotic)
Order of bone metastasis	Lumbar spine > femur > pelvis > thoracic spine > ribs
Oncologic emergency	Spinal cord compression → dexamethasone + emergency decompression
PSA nature	Organ-specific, not cancer-specific; produced by normal AND malignant epithelium
ADT mechanism (LHRH agonist)	Receptor downregulation → ↓LH → ↓testosterone
CRPC definition	Progression despite castrate testosterone (<50 ng/dL)
AR-V7 significance	Constitutively active AR; predicts ARPI resistance
BRCA2 clinical relevance	More aggressive; predicts PARP inhibitor response
New standard mHSPC	ADT + ARPI (enzalutamide/apalutamide/darolutamide)
Lutetium-PSMA	Targeted alpha therapy for mCRPC post-ARPI + taxane
5-year survival (localized)	~99%
5-year survival (distant metastasis)	~34% (SEER)

Sources: Campbell Walsh Wein Urology (9780323546423); Harrison's Principles of Internal Medicine 22e (9781265977061), Ch. 92; Robbins & Cotran Pathologic Basis of Disease (9780443264528), Ch. 21; EAU Guidelines on Prostate Cancer 2024 Part I (PMID 38614820) and Part II (PMID 38688773).That covers everything your professor is likely to ask at a 10-year urology specialist level. Here's a quick map of what was covered so you can navigate:

What you just got — section by section:

Epidemiology — incidence, mortality, racial/ethnic disparities, autopsy prevalence
Etiology & Risk Factors — family history, germline mutations (BRCA2, HOXB13, ATM), GWAS loci, diet, obesity, protective factors
Anatomy & Zones — why peripheral zone matters; contrast with BPH in transition zone
Pathogenesis — androgen/DHT/AR axis, TMPRSS2:ERG fusion, PTEN loss, AR mutations in CRPC, HGPIN as precursor
Pathology & Classification — histologic subtypes, gross/microscopic features, IHC markers (AMACR, p63, CK5), perineural invasion
Gleason Grading — patterns 1–5, grade groups 1–5 with descriptions, tertiary pattern rule
TNM Staging — full AJCC 8th edition clinical + pathological, risk stratification table
Clinical Manifestations — asymptomatic localized → LUTS → bone pain → spinal cord compression; lymphatic then hematogenous spread order; osteoblastic nature of bone mets
Diagnosis — PSA and all derivatives (PHI, 4K Score, free PSA), DRE, mpMRI/PI-RADS, biopsy techniques, PSMA PET, labs, germline/somatic testing
Clinical States Model — the modern framework (localized → BCR → nmCRPC → mHSPC → mCRPC)
Treatment — active surveillance, radical prostatectomy, radiation (EBRT/brachytherapy/SBRT), ADT mechanisms and agents, treatment intensification for mHSPC (ARPI, docetaxel, triplet), mCRPC therapies (taxanes, PARP inhibitors, lutetium-PSMA, Ra-223), nmCRPC
Prognosis — nomograms, Partin tables, PSA doubling time, 5-year survival by stage
Genomic Testing — Oncotype GPS, Decipher, Prolaris, MSI/BRCA testing
Screening Guidelines — AUA 2023, USPSTF, EAU 2024

The two most frequently tested "exam traps" at this level: the distinction between clinical vs. pathological T1 (pT1 does not exist in the surgical specimen), and the fact that Gleason score 6 is the minimum assigned today — patients mistakenly think it's "middle of the scale."

This is a shared conversation. Sign in to Orris to start your own chat.